DocumentRX-5310
Issued
Read3 min

Pfizer Pays $330M for Three Starna In Vivo CAR-T Programs

Pfizer will pay $330 million upfront for three preclinical Starna in vivo CAR-T programs, with up to $2.3 billion in milestones, royalties and rights outside Greater China.

TAG K-2547 · 548 words on the filing

Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
Pfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna DealKost9n4 / pixabay

Summary of findings

  • Pfizer will pay $330 million upfront for global rights outside Greater China to three preclinical programs.
  • The deal carries up to $2.3 billion in development and commercial milestones, plus royalties on approved products.
  • Pfizer will lead development outside Greater China and manufacture clinical-trial drug at U.S. facilities.
  • Xeljanz generated more than $1 billion in sales last year, although its key patents have expired.
  • The Wednesday agreement adds technology rights spanning inflammation, immunology and oncology.

Pfizer will pay $330 million upfront for global rights, excluding Greater China, to three preclinical Starna Therapeutics in vivo CAR-T programs for autoimmune diseases.

The agreement, announced Wednesday, adds up to $2.3 billion in potential development and commercial milestones, plus royalties on any approved products.

What did Pfizer acquire?

Pfizer also gains rights to use Starna’s proprietary in vivo cell-therapy technology across inflammation, immunology and oncology. Specific targets and indications under the pact remain undisclosed.

The deal brings Pfizer into in vivo cell therapy after it was absent from the field’s first wave. The three preclinical assets provide a foothold in the next generation of in vivo therapies.

“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short,” Michael Vincent, Pfizer’s chief inflammation and immunology officer, said in a prepared statement.

He added: “Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”

Why does Starna’s delivery technology matter?

Starna, based in Suzhou, China, develops RNA medicines delivered by lipid nanoparticles, or LNPs. Those particles commonly target the liver; Starna engineers them to address targets beyond it.

That capability supports in vivo CAR-T, in which a targeted RNA payload reaches a patient’s cells and reprograms them to become the therapy. The approach broadens cell therapy beyond oncology and into immunology.

The first CAR-T medicines to reach market were personalized cancer treatments made by engineering a patient’s own T cells. Their production requires an expensive, multistep manufacturing process.

In vivo treatments generate the therapeutic cells inside the body, eliminating the manufacturing and preparation steps required for ex vivo therapies.

How competitive is the in vivo field?

Pfizer is not the only large drug company moving into in vivo cell therapy. Eli Lilly and Johnson & Johnson each added candidates through business deals this year.

AstraZeneca, AbbVie, Gilead Sciences and Bristol Myers Squibb joined the field through acquisitions last year. Pfizer brings prior RNA experience through Comirnaty, the messenger RNA-based COVID-19 vaccine it developed with BioNTech.

Who will develop and manufacture the assets?

Pfizer will lead clinical development of the three Starna programs outside Greater China. The company also plans to manufacture drug for clinical trials at its U.S. facilities.

If the licensed assets lead to approved products, Pfizer will hold exclusive commercialization rights outside Greater China.

Pfizer also receives an option to exclusively license compounds created under a separate R&D collaboration. A second option would allow Pfizer to expand the agreement’s territory to include Greater China.

What does the deal mean for Pfizer’s immunology portfolio?

Pfizer’s top immunology drug, Xeljanz, is a small-molecule JAK inhibitor approved in several indications. Xeljanz generated more than $1 billion in sales last year, although its key patents have already expired.

The Starna programs add three preclinical autoimmune assets and a new delivery approach to that established commercial base. Pfizer remains responsible for paying $330 million upfront, with potential development and commercial milestones reaching $2.3 billion, plus royalties if the programs produce approved products.

via businesswire.com (Original)

Share this article:

More from Marcus Bennett

Marcus Bennett

Show full bio

News editor covering regulation, policy and their impact on global pharmaceutical industry at PharmInsider.

6 articles

Linked filings

  1. E-2578
  2. T-8005
  3. T-7393
  4. V-8592
  5. K-8919